- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03971929
Safety and Effect Study of SHR0532 (Drug Code) Tablets in Patients With Mild Hypertension
A Phase I, Randomized, Double-Blind, Placebo-hydrochlorothiazide Parallel Controlled, Multiple-Ascending Dose Study to Evaluate the Safety, Efficacy of SHR 0532 Oral Tablets in Mild Hypertension Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Hangzhou
-
Hangzhou, Hangzhou, China, 310009
- The Second Affiliated Hospital Zhejiang University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males or females between 18 to 65 years old
- Diagnosis of mild hypertension
- 18.5 kg/m2≤Body mass index (BMI) ≤35 kg/m^2
- Understand the study procedure and method, willing to participate the study and Informed consent form (ICF) signed in writing
Exclusion Criteria:
- History of significant drug allergy or allergic diseases (asthma, urticaria, eczematous dermatitis), or known allergy to anti hypertension drugs
- Anti-hypertensive drugs were taken within 1 month before screening
- History or at present patient has orthostatic hypotension
- History or at screening Participant has plasma sodium lower than 135mmol/L
- History or at screening visit/baseline patient has elevated serum uric acid (serum uric acid higher than ULN)
- Patients with type 1 diabetes mellitus need insulin therapy or poor blood glucose control (HbA1c > 9%, or oral anti diabetic drug dosage is not stable within 4 weeks before screening)
- History of arrhythmia or patient has clinically significant abnormalities of 12-lead ECG or prolonged corrected QT (QTc) interval (male > 450ms; female > 460ms) at screening visit
- History of New York Heart Association (NYHA) Definition II-IV Heart Failure
- Severe cardiovascular diseases occurred within 6 months before screening, including ischemic heart disease, peripheral vascular disease, significant ventricular tachycardia, atrial fibrillation, atrial flutter or other serious arrhythmias, hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortic stenosis, aortic or mitral valve disease of great hemodynamic significance, and severe cerebrovascular disease
- History of percutaneous intervention (PCI) or coronary artery bypass graft (CABG)
- History or active stroke, chronic seizures, or major neurological disorder
- History of osteoporosis, nephrocalcinosis, nephrolithiasis or hypercalciuria
- History or active malignant neoplastic disease. Exceptions: malignancies which have been successfully treated and non-recurrence >10 years prior to the screening visit
- Patients having following diseases may affect drug absorption, distribution, metabolism and excretion:
Gastrointestinal diseases such as irritable bowel syndrome, inflammatory bowel diseases including ulcerative colitis, Crohn's disease, malabsorption syndrome, microbial dysbiosis, intestinal infection; History of gastrointestinal operations, such as gastric resection and bypass, small intestinal resection and colonic resection which may affect drug absorption
- History of acute or chronic kidney diseases
- Dehydration or volume-depletion
- Clinically significant chronic or acute infectious diseases occur within 2 weeks before the start of the study (enrolment);
- Major surgery within 3 months before dosing
- Donation of blood/plasma within 1 month before dosing or blood/plasma (≥400 mL) within 3 months before dosing
- Unstable or severe urinary, digestive, psychiatric, neural, hematological and other diseases, or lab abnormalities, the investigators determine that participants in the study will be at unacceptable risk
Taking or having the following medication history:
- Participant need taking Cytochrome P450 3A4 (CYP3A4) inhibitors (such as ritonavir, indinavir, nelfinavir, erythromycin, telithromycin, clarithromycin, chloramphenicol, fluconazole, ketoconazole, itraconazole, verapamil or diltiazem) as well as strong/moderate CYP3A4 inducers (such as phenytoin, carbamazepine, oxcarbazepine, phenobarbital, efavirenz, nevirapine, rifampicin, modafinil, cyproterone or progestin) at least 2 weeks or 5 half-lives prior to administration of the initial dose of study drug until the post study visit
- Use of non-steroidal anti-inflammatory drugs (NSAIDs) at least 2 weeks before 1st dose of study drug until the post study visit
- use of systemic glucocorticoid therapy
Any laboratory examination result meet the following criteria at screening/baseline:
- Serum potassium < 3.5mmol/L or > 5.5mmol/L
- Serum creatinine more than ULN, Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) more than 2.0 x ULN or total bilirubin more than 1.5 x ULN at screening/baseline visit
- Creatinine kinase (CK) more than 3.0 x ULN at screening/baseline visit;
- Clinically significant abnormalities of coagulation and thyroid function
- HbsAg and Hepatitis B Virus (HBV)-DNA> 1000 cps/ml, Hepatitis C Virus Antibody (HCVAb), syphilis and HIV antibodies were positive at screening visit
- Serum pregnant test positive at screening/baseline visit
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: SHR0532 tablet
up to 3 cohorts of subjects will receive multiple dose of oral tablets
|
once daily(QD) for 4weeks
|
PLACEBO_COMPARATOR: SHR0532 placebo
up to 3 cohorts of subjects will receive multiple dose of oral SHR0532 placebo
|
once daily(QD) for 4weeks
|
ACTIVE_COMPARATOR: Hydrochlorothiazide
up to 3 cohorts of subjects will receive multiple dose of oral Hydrochlorothiazide 25mg
|
once daily(QD) for 4weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events(AEs) and Serious Adverse Events (SAEs)
Time Frame: from informed consent form signature to the end of the study (up to 2 months)
|
Incidence of AEs and SAEs, incidence of Treatment-Emergent Adverse Events, incidence of drug related adverse events (safety and tolrability)
|
from informed consent form signature to the end of the study (up to 2 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Clinic Systolic Blood Pressure (SBP) and Clinic Diastolic Blood Pressure (DBP)
Time Frame: Baseline to end of the study (up to 32 days)
|
Each subject has their office blood pressure every day of each treatment period (total of 28 days of treatment).
The difference between baseline and D28 of each office BP value are calculated and recorded.
|
Baseline to end of the study (up to 32 days)
|
Change from baseline in 24h Urine sodium
Time Frame: from baseline to Day 8; from D28 to D32 (up to 32 days)
|
Urine sodium (Na) levels were measured over 24-hours and different time period of 24 hours on Day -1 (baseline) and on Day 1to Day 7, Day28 to Day 32.
The total amount of Na excreted in the Urine for Day-1 (baseline) and Day1 to Day 7, Day 28 to Day 32 were calculated and recorded and the difference between the 2 values are recorded.
|
from baseline to Day 8; from D28 to D32 (up to 32 days)
|
Change from baseline in 24h Urine Volume
Time Frame: from baseline to Day 8; from D28 to D32 (up to 32 days)
|
Urine Volume were measured over 24-hours and different time period of 24 hours on Day -1 (baseline) and on Day 1to Day 7, Day28 to Day 32.The total amount of Urine excreted for Day-1 (baseline) and Day1 to Day 7, Day 28 to Day 32 were calculated and recorded and the difference between the 2 values are recorded.
|
from baseline to Day 8; from D28 to D32 (up to 32 days)
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SHR0532-102
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Addpharma Inc.Completed
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Cytos Biotechnology AGCompletedMild Essential Hypertension | Moderate Essential HypertensionSwitzerland
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
Clinical Trials on SHR0532
-
Jiangsu HengRui Medicine Co., Ltd.Unknown